Deal To Watch: Early Cancer Detection Through Blood Tests

$10M

Key Stats: Delee on Republic

Valuation Cap

$10M

Amount Raised

$1,070,000

Number of Investors

4,888

Minimum Raise

$75,000

Maximum Raise

$1,070,000

Likelihood of Max Exceeded
Start Date

12/11/2019

Stop Date

04/24/2020

Days Remaining

Closed

Security Type

SAFE

Investment Minimum

$50

Deal Analytics

Click Here

Summary

Delee has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected into the top 10%-20% of our due diligence funnel. If you have questions regarding our deal diligence and selection methodology, please reach out to hello@kingscrowd.com.

The Problem

While there have been significant advances in treating cancer, it is forecasted that cancer rates will increase by more than 50% and death rates will almost double in the next twenty years. Currently, cancer screening is available for specific forms of cancer such as breast, colon, prostate, lung, and others. These tests can only detect the cancer once it has formed in the body and begun to take hold. They do so by imaging a specific area, which requires significant human touch to identify, gather, and assess. Additionally, cancer tests are expensive and generally not ordered unless there is a known risk. 

Advances in cancer treatment have dramatically reduced the number of fatalities, but the key to this is early detection. The earlier the cancer is detected the higher the probability of beating it.

It is widely believed that cancer can begin developing in the body as early as 12 years before clinical symptoms appear. What if there were a simple blood test that could detect cancer when it was at the minute cellular level before it caused any problems?

The Solution

Delee has created CrytoCatch, which uses a blood sample to detect 1 tumor cell out of 37.5 billion blood cells. This small machine initiates a rapid process in as little as 15 minutes to isolate a single tumor cell, thus identifying the start of cancer unimaginably early.

How is this possible?

In the majority of cancers, when a tumor develops, even if it is still localized, it releases malignant cells into the bloodstream, called circulating tumor cells (CTC). These cells have a key role in the establishment of metastasis in other organs.

Customers

CytoCatch is on track to be the second FDA approved CTC test by 2023. It will be the first for early detection of cancer, and it will provide valuable feedback for increasing the efficacy of cancer treatments. Prior to FDA clearance, CytoCatch will be marketed as a powerful research tool for pharmaceutical companies and researchers to improve their cancer treatment research.  

Competitors

CTC, the core technology in CytoCatch, was first given Current Procedural Technology codes at the beginning of 2013. Those codes are necessary to bill Medicare and insurance companies. CellSearch received FDA approval for its CTC technology in 2004 for monitoring metastatic breast cancer. It has gained further FDA approval for monitoring very specific cancer treatments. CellSearch, like the majority of CTC research, is used to evaluate the progress of a patient’s cancer treatment. This technology enables a more comprehensive assessment of whether the cancer is shrinking or growing after the cancer has been identified through clinical symptoms.  

Currently, CellSearch remains the only FDA approved CTC product on the market. There is no indication of a direct competitor to CytoCatch, which is focused on identifying cancer long before any known test.

Team

Liza Velarde, CEO, and Co-Founder – Ms. Velarde’s charisma leaps through the phone. She has a passion for her company and is quick to identify gaps she and her co-founders have and how she has been able to access experts to fill those gaps. 

She started Delee while finishing her degree summa cum laude at Tecnologico de Monterrey. According to Delee’s marketing, Ms. Velarde is responsible for creating the company’s relationships with hospitals and research institutions. She was awarded the prestigious Cartier Women’s Initiative Award and the WeXchange. In 2019, she also co-founded Zen Fluidics, a line of products to empower researchers to develop unique microfluid applications.

Why We Like it

  • Model: Delee is uniquely positioned for revenue pre-FDA and post-FDA approval. The post-FDA approval is the most lucrative part of Delee’s business model, but it is noteworthy for Delee’s innovation to have revenue before FDA approval.
    • Delee will sell the CytoCatch machine to researchers prior to FDA approval. In addition to the sales price of the machine, Delee will gain revenues via sales of the necessary reagents and consumables to perform each test.
  • Market Gap: Delee’s strategy is to attack cancer detection before there are any clinical symptoms. This innovation is a market gap many do not have the imagination to pursue. Further, Delee intends to begin testing for prostate cancer first. This focus will be a significant step in cancer treatment because, according to Ms. Velarde, women’s cancer is currently the only one with an early detection test. Providing a male cancer screening will be a significant step for male cancer treatment and will further differentiate Delee’s product.
  • Clinical Trials: To save money on costly clinical trials, trials will be conducted in Monterrey, Mexico. Delee will pursue United States FDA approval but all testing and engineering will occur in Mexico, allowing significant cost savings.

The Rating: Deal To Watch

“Cancer is curable, the problem is the lack of timely information.” – Ms. Velarde 

Ms. Velarde has the type of drive and vision to realize the seemingly impossible with CytoCatch. While she was still at University, during an elevator ride, she pitched Delee to the Heineken CEO Jean-Francois van Boxmeer and convinced him to donate funds to the first prototype.

The Delee team is using an almost twenty-year-old technology, CTC, which never gained the expected promise with still only one FDA approved product in the market. While cancer treatment is a very crowded market, diagnosis before clinical symptoms is not. This young, energetic team might just have the formula to radically change cancer.

Invest Today
19
About: Meridith taylor

Meridith Blank Taylor has spent the past two decades providing strategic guidance to early stage businesses. Meridith has a BA from the University of Pennsylvania and an MBA in Finance from the University of Chicago.

View Meridith taylor's deals

This is a Kingscrowd Crowd Article

Gain access to the best rated startups across all major platforms including Wefunder, Republic, StartEngine, SeedInvest, Netcapital and more...